Overview
Current Appointments & Affiliations
Professor of Medicine
·
2024 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2000 - Present
Duke Cancer Institute,
Institutes and Centers
In the News
View All News
Recent Publications
Genomic landscape of malignant phyllodes tumors reveals multiple targetable opportunities.
Conference Oncologist · December 6, 2024 BACKGROUND: Malignant phyllodes tumors (MPT) are rare fibroepithelial breast cancers with no known effective systemic therapy; metastatic progression portends a dismal prognosis. We sought to describe the genomic landscape of MPTs through genomic profiling ... Full text Link to item CiteProspective evaluation of quantitative response parameter in patients with Gastrointestinal Stroma Tumor undergoing tyrosine kinase inhibitor therapy-Impact on clinical outcome.
Journal Article Int J Cancer · December 1, 2024 The purpose of this study was to determine if dual-energy CT (DECT) vital iodine tumor burden (ViTB), a direct assessment of tumor vascularity, allows reliable response assessment in patients with GIST compared to established CT criteria such as RECIST1.1 ... Full text Link to item CiteConsensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: A report from the National Ewing Sarcoma Tumor Board.
Journal Article Cancer · December 1, 2024 Ewing sarcoma (ES) is a malignant tumor of bone and soft tissue that most often occurs in children, adolescents, and young adults. Debate and controversy remain in the management of relapsed/refractory ES (RR-ES). The authors leveraged the expertise assemb ... Full text Link to item CiteRecent Grants
A Phase II, Multi-centre, Randomised, Double-blind, Group Comparator Trial to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Patients with Tenosynovial Giant Cell Tumour,
Clinical TrialPrincipal Investigator · Awarded by SynOx Therapeutics Ltd · 2025 - 2030A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, InoperaBLE,orMetastatic
Clinical TrialPrincipal Investigator · Awarded by Intensity Therapeutics, Inc. · 2024 - 2029A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ?18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1
Clinical TrialPrincipal Investigator · Awarded by Servier Bio-Innovation, LLC · 2024 - 2029View All Grants
Education, Training & Certifications
Thomas Jefferson University ·
2000
M.D.